Table 1.
CDH22 staining and clinicopathological characteristics of melanoma patients
| CDH22 staining | ||||
|---|---|---|---|---|
| Variables | Negative (%) | Positive (%) | Total | P valuea |
| Primary Melanoma | ||||
| Age | ||||
| <60 | 15(13.5%) | 96(86.5%) | 111 | 0.81 |
| ≥60 | 17(12.5%) | 119(87.5%) | 136 | |
| Gender | ||||
| Male | 17(12.3%) | 121(87.7%) | 138 | 0.74 |
| Female | 15(13.8%) | 94(86.2%) | 109 | |
| Tumour subtype | ||||
| Acrolentigous | 0(0%) | 8(100%) | 8 | 0.60 |
| Lentigous | 3(8.3%) | 33(91.7%) | 36 | |
| Nodular | 6(12.5%) | 42(87.5%) | 48 | |
| Superficial spreading | 11(13.3%) | 72(86.7%) | 83 | |
| Other | 12(16.7%) | 60(83.3%) | 72 | |
| Siteb | ||||
| Sun-protected | 22(13.6%) | 140(86.4%) | 162 | 0.70 |
| Sun-exposed | 9(11%) | 73(89%) | 82 | |
| Unspecified | 0(0) | 3(100%) | 3 | |
| Metastatic Melanoma | ||||
| Age | ||||
| <60 | 21(26.9%) | 57(73.1%) | 78 | 0.10 |
| ≥60 | 10(13.4%) | 55(84.6%) | 65 | |
| Gender | ||||
| Male | 16(17.2%) | 77(82.8%) | 93 | 0.08 |
| Female | 15(30%) | 35(70%) | 50 | |
a
χ2 test
b
Sun-protected sites: arm, back, leg, trunk, and vulva; Sun-exposed sites: face, head, and neck.